GAS6 and Sepsis: Clinically, GAS6/AXL pathway activators or related drugs could offer a novel therapeutic strategy for treating SAE by enhancing microglia’s anti-inflammatory and clearance capabilities, potentially improving neurological outcomes in sepsis patients.